Cisen Pharmaceutical Co (SHSE:603367) Other Current Liabilities: ¥225 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603367 Cisen Pharmaceutical Co Ltd SHSE:603367
68 GF Score
Price ¥14.90
GF Value ¥14.45
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Cisen Pharmaceutical Co Other Current Liabilities?

Cisen Pharmaceutical Co SHSE:603367 -0.67% 68 Other Current Liabilities is ¥225 Mil as of Jun. 2026. GuruFocus rates SHSE:603367 with a GF Score™ of 68/100 and a GF Value™ of ¥14.45 (Fairly Valued). The stock has 3 warning signs investors should review.

Cisen Pharmaceutical Co's other current liabilities for the quarter that ended in Jun. 2026 was ¥225 Mil.

Cisen Pharmaceutical Co's quarterly other current liabilities declined from Dec. 2025 (¥258 Mil) to Mar. 2026 (¥197 Mil) but then increased from Mar. 2026 (¥197 Mil) to Jun. 2026 (¥225 Mil).

Cisen Pharmaceutical Co's annual other current liabilities declined from Dec. 2023 (¥405 Mil) to Dec. 2024 (¥403 Mil) and declined from Dec. 2024 (¥403 Mil) to Dec. 2025 (¥258 Mil).

Cisen Pharmaceutical Co Other Current Liabilities Related Terms

Cisen Pharmaceutical Co Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Cisen Pharmaceutical Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cisen Pharmaceutical Co Other Current Liabilities Chart

Cisen Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 317.88 396.43 404.56 403.44 257.74

Cisen Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 253.21 123.54 257.74 196.88 224.76
SHSE:603367
68GF Score
Cisen Pharmaceutical Co Ltd SHSE:603367
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cisen Pharmaceutical Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ¥225 Mil mean?
Cisen Pharmaceutical Co (SHSE:603367) has a Other Current Liabilities of ¥225 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Cisen Pharmaceutical Co.
Is Cisen Pharmaceutical Co's Other Current Liabilities too high?
Cisen Pharmaceutical Co's current Other Current Liabilities is ¥225 Mil. Overall, Cisen Pharmaceutical Co has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cisen Pharmaceutical Co's Other Current Liabilities compare to ZTS?
Cisen Pharmaceutical Co's Other Current Liabilities of ¥225 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Cisen Pharmaceutical Co. Cisen Pharmaceutical Co's current Other Current Liabilities is ¥225 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cisen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Cisen Pharmaceutical Co (SHSE:603367) is currently considered Fairly Valued. The stock's GF Value™ is ¥14.45, compared to a current price of ¥14.90 — trading 3.1% above its estimated fair value. The current Other Current Liabilities is ¥225 Mil. Cisen Pharmaceutical Co's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Cisen Pharmaceutical Co (SHSE:603367), the current Other Current Liabilities is ¥225 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cisen Pharmaceutical Co (SHSE:603367) Overvalued in 2026?

Based on GuruFocus' analysis, Cisen Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥14.90 is trading 3.1% above its estimated GF Value™ of ¥14.45. GuruFocus considers Cisen Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:603367:

  • Other Current Liabilities: ¥225 Mil
  • GF Value™: ¥14.45 vs. price of ¥14.90 (3.1% above fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the SHSE:603367 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cisen Pharmaceutical Co Business Description

Address Tongji Sci-tech Industrial Park, High-tech Industrial Development Zone, Shandong, Jining, CHN, 272073
Cisen Pharmaceutical Co Ltd is the pharmaceutical company in China. The company's main business is the development, production and sales of pharmaceutical products, mainly in the production of chemical preparations. Its product offering includes chemical drug preparations such as liver disease drug, antitumor and auxiliary drugs, nutrition preparation, cardiovascular class, antibiotics, sedation anaesthesia snooze, digestive system agents; and healthcare products.
68GF Score

Get the complete analysis for SHSE:603367

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥14.90
Price
¥14.45
GF Value